Prior to joining A&M, Dr. Eisenhardt spent eight years with KPMG in Hamburg, Munich and Zurich, where he most recently led KPMG’s Strategy group in Switzerland. For the last eight years, he built up and led the M&A Separation & Integration practice for Bayer AG globally. Dr. Eisenhardt worked on several transformations for leading global corporates as well as medium-sized companies in chemicals, pharmaceuticals, consumer health, agriculture and life sciences.

Dr. Eisenhardt’s exemplary projects include the value creation concept versus liquidation assessment and implementation ($12 million savings) for Bayer's digital VMS business (U.S.); integration and collaboration concept for Bayer Pharma’s pipeline acquisitions; ecosystem development for the acquisition of innovative and fast-growing companies within a global firm; transformation along all functions of Bayer’s Environmental Science business with a subsequent divestment for PE buyers (deal volume $2.6 billion); efficiency program for Bayer’s Animal Health Division with a subsequent divestment (deal volume $7.6 billion); value creation and separation concept of Bayer's infrastructure business, Currenta (deal volume €3.5 billion); divestments of Bayer’s dermatology business, Coppertone and Dr. Scholls businesses as well as a large array of pharma and consumer brands/ products; operationalization of forced antitrust divestments negotiations on 10+ deals in context of a $66 billion deal; joint venture implementation for Nestlé; and transformation execution for GSK/Novartis’ portfolio strategy.

Dr. Eisenhardt studied law in Freiburg, Kiel and Hamburg (bar exam); earned a PhD in law from Kiel University; and earned an MBA from the European School of Management and Technology (ESMT) in Berlin.